drugset / Trial / NCT03188198
Risk Adapted Therapy in Diffuse Large B Cell Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized phase II trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.
Timeline
- Start
- 2016-06-01
- Primary completion
- 2018-06-01
- Completion
- 2019-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 10 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Prednisone | Other / unclassified | 40 mg/m2 | Oral |
| Subject | Prednisone | Other / unclassified | 60 mg/m2 | Oral |
| Subject | Vincristine | Small molecule | 0.4 mg/m2 | Intravenous |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | filgrastim | Protein / enzyme biologic | 480 ug | Subcutaneous |